See the DrugPatentWatch profile for ruxolitinib

After conducting a thorough search, I was unable to find the exact US filing date for Apotex's Ruxolitinib ANDA (Abbreviated New Drug Application) on DrugPatentWatch.com or any other publicly available source. However, according to the FDA's Orange Book, Ruxolitinib is a Janus kinase (JAK) inhibitor, approved for the treatment of certain myeloproliferative neoplasms (MPNs) under the brand name Jakafi, owned by Incyte Corporation [1].

The patents for Jakafi have expired, allowing for the development of generic versions. Apotex, a Canadian pharmaceutical company, is one of the manufacturers that have filed an ANDA for Ruxolitinib [2].

It is important to note that the US filing date for Apotex's Ruxolitinib ANDA is not publicly disclosed on DrugPatentWatch.com or other sources at the time of this writing [3].

Sources:

1. [FDA Orange Book - Ruxolitinib](https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm?drugname=ruxolitinib)
2. [Apotex Inc. - Generic Drugs](https://www.apotex.com/our-products/generic-drugs)
3. [DrugPatentWatch - Ruxolitinib](https://www.drugpatentwatch.com/drugs/ruxolitinib)